Second-look TURBT showed limited value in altering outcomes for high-grade Ta bladder cancer after complete resection.

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to minimize the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

TURBT was associated with persistent sexual dysfunction in men, pointing to the importance of incorporating sexual health into postoperative evaluation.

The multicenter ENVISION trial included 240 adults who had recurred after TURBT and who had multiple tumors, a solitary tumor > 3 cm, and/or a recurrence within 1 year of TURBT.

"For decades, TURBT has been the standard approach for bladder cancer treatment. That’s why innovative treatments like ZUSDURI are essential, especially for those adult patients with recurrent ...

At the 3-month evaluation, the CR rate was 64.8% for those receiving TURBT, whereas the CR rate for the UGN-102 group was slightly lower at 63.6%. 2 Nevertheless, at the 12-month follow-up, 79.7% ...

In addition, FDA staff said that genitourinary symptoms were greater with UGN-102 than with TURBT. UGN-102 was also evaluated in the randomized ATLAS trial, which compared UGN-102 with or without ...

The 15-month disease-free survival rates were 72% and 50%, respectively. Furthermore, the FDA notes that the overall burden of TURBT in the UGN-102 group was lower as well.

Additionally, the FDA questioned the long-term benefits of UGN-102, citing a lack of data on future treatments and its potential to reduce the frequency of TURBT procedures in certain patient ...

The multi-centre, open-label, global study is assessing the combo in 1,018 BCG-naïve NMIBC subjects after undergoing transurethral resection of bladder tumour (TURBT).